Monday

26th Feb 2024

EU to buy 1.8bn BioNTech jabs, in switch to mRNA vaccines

  • The vaccines developed by Pfizer/BioNTech and Moderna use 'new messenger RNA' (mRNA) technology to trigger an immune response (Photo: Arne Müseler)

The European Commission president Ursula von der Leyen on Wednesday (14 April) announced the bloc has entered negotiations to buy 1.8 billion doses of the Pfizer/BioNtech vaccine - to be delivered between now and 2023.

She also confirmed that member states will receive, starting this month, 50 million additional Pfizer/BioNtech Covid-19 vaccines, as doses initially expected at the end of 2021 were brought forward to the second quarter.

Read and decide

Join EUobserver today

Get the EU news that really matters

Instant access to all articles — and 20 years of archives. 14-day free trial.

... or subscribe as a group

In total, the company will supply the EU with 250 million doses from April to June.

Notably, von der Leyen expressed full confidence in Pfizer/BioNtech, saying that it has proven to be "a reliable partner" in both its product and its contractual commitments.

"We need to focus on technologies that have proven their worth," she said.

The announcement comes after Italian newspaper La Stampa reported on Wednesday that the EU executive has decided not to renew the contracts with AstraZeneca and Johnson & Johnson for 2022.

"The European Commission, in agreement with the leaders of many [EU] countries, has decided that the contracts with the companies that produce [viral vector] vaccines that are valid for the current year will not be renewed at their expiry," the newspaper stated.

It added that the EU executive will focus on the so-called mRNA vaccines, such as those developed by Pfizer/BioNTech and Moderna, which uses new messenger RNA (mRNA) technology to trigger an immune response.

Brussels has yet to confirm that report, but a commission spokesperson told EUobserver that the institution is keeping "all options open to be prepared for the next stages of the pandemic, for 2022 and beyond".

However, following talks with the EU executive, the European People's Party MEP, Pieter Liese - who is also a medical doctor - stated that that "the European Commission will no longer buy vaccines from Johnson & Johnson and AstraZeneca".

"The future belongs to mRNA vaccines," he said, adding that these jabs are more effective than the vector vaccines (such as AstraZeneca or Johnson & Johnson), seem to have fewer side effects, and can be adapted to mutations more quickly.

'Race against time'

So far, EU member states have received over 126 million vaccines, of which more than 100 million have already been used - with some 27 million Europeans being already fully vaccinated.

"We are in a race against time," von der Leyen said, adding that "the faster we reach our target of having 70 percent of the adult population in Europe vaccinated, the better the chances of containing the virus."

However, she also pointed out that "there are still many factors that can disrupt the planned delivery schedule of vaccines".

One of those was the recommendation earlier this week by US health authorities for a "pause" of the Johnson & Johnson vaccine over reports of very rare cases of bloc clots, which led to the pharmaceutical company deciding to delay the roll-out of its Covid-19 vaccine in Europe.

The European Medicine Agency said it is reviewing the reported cases of blood clots that occurred in the US, and a recommendation is expected next week.

"While its review is ongoing, EMA remains of the view that the benefits of the vaccine in preventing Covid-19 outweigh the risks of side effects," it said in a statement.

The EU had signed a contract with Johnson & Johnson for 200 million doses to be delivered this year - with the option for member states to purchase an additional 200 million.

Meanwhile, Denmark announced Tuesday it would stop using the AstraZeneca vaccine completely over suspected rare side effects.

Column

BioNTech: Stop talking about their 'migration background'

I understand that the German-Turkish community - often subjected to condescension in Germany - celebrated the story. Uğur Şahin and Özlem Türecki represent scientific excellence and business success at the highest level.

China responds to 'low-efficacy' vaccine fears

Concern over the low efficiency of Chinese-made vaccines has been mounting since China's top official said existing vaccines offer low protection against Covid-19 - raising questions for those nations relying heavily on the Chinese jabs. That includes Hungary and Serbia.

EU defends all vaccines, amid lower AstraZeneca take-up

The European Commission said that bloc's strict regulatory process for the evaluation and approval of vaccines is crucial to persuade citizens to get the jab, calling on member states to fight vaccine hesitancy with information.

'Shocking' disparities bolster vaccine patent-waiver call

The unbalanced distribution of vaccines globally has triggered calls to waive intellectual property rights for Covid-19 vaccines. But an analysis of lobbying by watchdog Corporate Europe Observatory revealed how Big Pharma has influenced the EU Commission's position.

EU exported over one billion vaccines so far

The EU has exported more than one billion doses of Covid-19 vaccines this year, and announced it will donate 500 million extra doses to poorer countries in the coming months.

Opinion

EU plan to let 17-year olds drive trucks is crazy

It's an astonishing proposition rooted in political interest rather than facts, with potentially dire consequences for all road users — especially for people who walk and cycle, warns the European Cycling Federation.

EU deal on new gig-workers rules unlikely before June elections

Another provisional agreement on improving working conditions for platform workers fall apart on Friday, as four member states decided not to support it — making the chances of a directive before the June European elections unlikely.

Latest News

  1. EU rewards Tusk's Poland on rule of law with €137bn
  2. UK-EU relations defrosting ahead of near-certain Labour win
  3. EU paid Russia €420-per-capita for fossil fuels since war began
  4. After two years of war, time to hit Putin's LNG exports
  5. Creating the conditions for just peace in Ukraine
  6. Energy and minerals disputes overshadow new EU-ACP pact
  7. Germany speeds up Georgia and Morocco asylum returns
  8. How Amazon lobbyists could be banned from EU Parliament

Stakeholders' Highlights

  1. Nordic Council of MinistersJoin the Nordic Food Systems Takeover at COP28
  2. Nordic Council of MinistersHow women and men are affected differently by climate policy
  3. Nordic Council of MinistersArtist Jessie Kleemann at Nordic pavilion during UN climate summit COP28
  4. Nordic Council of MinistersCOP28: Gathering Nordic and global experts to put food and health on the agenda
  5. Friedrich Naumann FoundationPoems of Liberty – Call for Submission “Human Rights in Inhume War”: 250€ honorary fee for selected poems
  6. World BankWorld Bank report: How to create a future where the rewards of technology benefit all levels of society?

Stakeholders' Highlights

  1. Georgia Ministry of Foreign AffairsThis autumn Europalia arts festival is all about GEORGIA!
  2. UNOPSFostering health system resilience in fragile and conflict-affected countries
  3. European Citizen's InitiativeThe European Commission launches the ‘ImagineEU’ competition for secondary school students in the EU.
  4. Nordic Council of MinistersThe Nordic Region is stepping up its efforts to reduce food waste
  5. UNOPSUNOPS begins works under EU-funded project to repair schools in Ukraine
  6. Georgia Ministry of Foreign AffairsGeorgia effectively prevents sanctions evasion against Russia – confirm EU, UK, USA

Join EUobserver

EU news that matters

Join us